Lentivirally transduced dendritic cells as a tool for cancer immunotherapy

Journal of Gene Medicine

Volumn 5, Issue 8, 2003, Pages 654-667

  Breckpot, Karine ^a   Dullaers, Melissa ^a   Bonehill, Aude ^a   Van Meirvenne, Sonja ^a   Heirman, Carlo ^a   De Greef, Catherine ^a   van der Bruggen, Pierre ^b   Thielemans, Kris ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

Author keywords

Cytotoxic T cell; Dendritic cell; Immunotherapy; Lentivirus; T helper cell

Indexed keywords

LENTIVIRUS VECTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELANOMA ANTIGEN 3; NERVE GROWTH FACTOR RECEPTOR; OVALBUMIN; INTERLEUKIN 12; MAGEA3 PROTEIN, HUMAN; MAGEB3 PROTEIN, MOUSE; TUMOR ANTIGEN; TUMOR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL CLONING; CELL VIABILITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG MECHANISM; FEMALE; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; GENE VECTOR; GENETICS; IMMUNOLOGY; LENTIVIRINAE; METABOLISM; NEOPLASM; PHYSIOLOGY; SURVIVAL RATE; T LYMPHOCYTE; VIROLOGY;

ANIMALS; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CELL LINE; DENDRITIC CELLS; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; INTERLEUKIN-12; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM PROTEINS; NEOPLASMS; SURVIVAL RATE; T-LYMPHOCYTES; TRANSDUCTION, GENETIC;

EID: 0842312143     PISSN: 1099498X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jgm.400     Document Type: Article

References (54)

1. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002; 188: 51-64.
2. Pardoll DM. Cancer vaccines. Trends Pharmacol Sci 1993; 14: 202-208.
3. Pardoll DM. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238.
4. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767-811.
5. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271-296.
6. Steinman RM, Inaba K, Turley S, et al. Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol 1999; 60: 562-567.
7. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16.
8. Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Annu Rev Immunol 2000; 18: 245-273.
9. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 1999; 50: 507-529.
10. Mayordomo JI, Zorina T, Storkus WJ, et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med 1995; 1: 1297-1302.
11. Zitvogel L, Mayordomo JI, Tjandrawan T, et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87-97.
12. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-332.
13. Schuler-Thurner B, Schultz ES, Berger TG, et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 2002; 195: 1279-1288.
14. De Veerman M, Heirman C, Van Meirvenne S, et al. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity. J Immunol 1999; 162: 144-151.
15. Kalams SA, Walker BD. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188: 2199-2204.
16. Toes RE, Ossendorp F, Offringa R, et al. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999; 189: 753-756.
17. Li Q, Yu B, Grover AC, et al. Therapeutic effects of tumor reactive CD4+ cells generated from tumor-primed lymph nodes using anti-CD3/anti-CD28 monoclonal antibodies. J Immunother 2002; 25 304-313.
18. Dorothee G, Vergnon I, Menez J, et al. Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 2002; 169: 809-817.
19. Qin Z, Blankenstein T. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 2000; 12 677-686.
20. Schnell S, Young JW, Houghton AN, et al. Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: implications for the clinical use of dendritic cells. J Immunol 2000; 164: 1243-1250.
21. Pieters J, Bakke O, Dobberstein B. The MHC class II-associated invariant chain contains two endosomal targeting signals within its cytoplasmic tail. J Cell Sci 1993; 106: 831-846.
22. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996; 272: 263-267.
23. Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-9880.
24. Vigna E, Naldini L. Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy. J Gene Med 2000; 2: 308-316.
25. Chinnasamy N, Chinnasamy D, Toso JF, et al. Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum Gene Ther 2000; 11: 1901-1909.
26. Lewis PF, Emerman M. Passage through mitosis is required for oncoretroviruses but not for the human immunodeficiency virus. J Virol 1994; 68: 510-516.
27. Follenzi A, Ailles LE, Bakovic S, et al. Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 2000; 25: 217-222.
28. Zufferey R, Nagy D, Mandel RJ, et al. Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-875.
29. Chinnasamy D, Chinnasamy N, Enriquez MJ, et al. Lentiviral-mediated gene transfer into human lymphocytes: role of HIV-1 accessory proteins. Blood 2000; 96: 1309-1316.
30. Miyoshi H, Blomer U, Takahashi M, et al. Development of a self-inactivating lentivirus vector. J Virol 1998; 72: 8150-8157.
31. Zennou V, Petit C, Guetard D, et al. HIV-1 genome nuclear import is mediated by a central DNA flap. Cell 2000; 101 173-185.
32. Zufferey R, Donello JE, Trono D, et al. Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 1999; 73: 2886-2892.
33. Van Meirvenne S, Straetman L, Heirman C, et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002; 9: 787-797.
34. Schultz ES, Lethe B, Cambiaso CL, et al. A MAGE-A3 peptide presented by HLA-DP4 is recognized on tumor cells by CD4+ cytolytic T lymphocytes. Cancer Res 2000; 60: 6272-6275.
35. Schultz ES, Zhang Y, Knowles R, et al. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens 2001; 57: 103-109.
36. Naldini L, Blomer U, Gage FH, et al. Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci USA 1996; 93: 11382-11388.
37. Tuyaerts S, Noppe SM, Corthals J, et al. Generation of large numbers of dendritic cells in a closed system using cell factories. J Immunol Methods 2002; 264: 135-151.
38. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
39. Chaux P, Vantomme V, Stroobant V, et al. Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 1999; 189: 767-778.
40. Van Tendeloo VF, Snoeck HW, Lardon F, et al. Nonviral transfection of distinct types of human dendritic cells: high-efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther 1998; 5: 700-707.
41. Zhong L, Granelli-Piperno A, Pope M, et al. Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus. Eur J Immunol 2000; 30: 3281-3290.
42. Dietz AB, Vuk-Pavlovic S. High efficiency adenovirus-mediated gene transfer to human dendritic cells. Blood 1998; 91: 392-398.
43. Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999; 163: 699-707.
44. Amado RG, Chen IS. Lentiviral vectors - the promise of gene therapy within reach? Science 1999; 285: 674-676.
45. Follenzi A, Sabatino G, Lombardo A, et al. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther 2002; 13: 243-260.
46. Kim VN, Mitrophanous K, Kingsman SM, et al. Minimal requirement for a lentivirus vector based on human immunodeficiency virus type 1. J Virol 1998; 72: 811-816.
47. Firat H, Zennou V, Garcia-Pons F, et al. Use of a lentiviral flap vector for induction of CTL immunity against melanoma. Perspectives for immunotherapy. J Gene Med 2002; 4: 38-45.
48. Manganini M, Serafini M, Bambacioni F, et al. A human immunodeficiency virus type 1 pol gene-derived sequence (cPPT/CTS) increases the efficiency of transduction of human nondividing monocytes and T lymphocytes by lentiviral vectors. Hum Gene Ther 2002; 13 1793-1807.
49. Haas DL, Case SS, Crooks GM, et al. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Mol Ther 2000; 2: 71-80.
50. Metharom P, Ellem KA, Schmidt C, et al. Lentiviral vector-mediated tyrosinase-related protein 2 gene transfer to dendritic cells for the therapy of melanoma. Hum Gene Ther 2001; 12: 2203-2213.
51. Rouas R, Uch R, Cleuter Y, et al. Lentiviral-mediated gene delivery in human monocyte-derived dendritic cells: optimized design and procedures for highly efficient transduction compatible with clinical constraints. Cancer Gene Ther 2002; 9: 715-724.
52. Esslinger C, Romero P, MacDonald HR. Efficient transduction of dendritic cells and induction of a T-cell response by third-generation lentivectors. Hum Gene Ther 2002; 13: 1091-1100.
53. Dyall J, Latouche JB, Schnell S, et al. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 2001; 97: 114-121.
54. Bennett SR, Carbone FR, Karamalis F, et al. Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help. J Exp Med 1997; 186: 65-70.